Welcome to our dedicated page for Cellev8 Nutrition news (Ticker: CELV), a resource for investors and traders seeking the latest updates and insights on Cellev8 Nutrition stock.
Cellev8 Nutrition Inc. (OTC: CELV), formerly Preferred Commerce, generates news primarily around its Superoxide Dismutase (SOD)–based nutraceuticals, cellular health technology, and partnerships in sports and wellness. Company announcements highlight its focus on antioxidant defense, recovery, metabolic health, and the use of patent-pending delivery systems to enhance SOD absorption through gummy formulations.
News coverage often features product launches and enhancements, such as the SlimCell™ GLP‑1 support and weight management gummy, inflammation and recovery gummies, and focus and memory products. Releases describe the science behind ingredients like SOD B® Dimpless, Morosil™, and Melorun®, along with data from supplier clinical trials and the company’s emphasis on cellular protection, oxidative stress reduction, and body composition support.
Cellev8 also issues updates on strategic collaborations and endorsements. These include multi-year partnerships with Pro Football Hall of Famer Andre Reed, joint marketing ventures with Vivos Therapeutics for obstructive sleep apnea–related wellness, and a collaborative sales agreement with Zyppah targeting snoring and sleep health. The company highlights adoption by professional and collegiate sports teams and its NSF Certified for Sport accreditation for its SOD-based gummy.
Investors and followers can expect news on patent filings for delivery systems, advisory board additions in functional medicine and sports nutrition, shareholder updates on distribution through channels such as Amazon, Vitacost, and Walmart online, and developments in licensing opportunities for its encapsulation technology. This page offers a central view of CELV’s press releases and corporate communications for those tracking its progress in the nutraceutical and sports performance markets.
Summary not available.